{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:52:38Z","timestamp":1791499958642,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017534","name":"333 Project of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017534","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003512","name":"State Administration of Foreign Experts Affairs","doi-asserted-by":"publisher","award":["B18056"],"award-info":[{"award-number":["B18056"]}],"id":[{"id":"10.13039\/501100003512","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574278"],"award-info":[{"award-number":["82574278"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119359","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:06:40Z","timestamp":1790694400000},"page":"119359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Targeting the nonenzymatic scaffold function of RIPK1 via a VHL-recruiting PROTAC synergizes with immunotherapy in melanoma"],"prefix":"10.1016","volume":"321","author":[{"given":"Shunxin","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingze","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6729-4443","authenticated-orcid":false,"given":"Pei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5044-3721","authenticated-orcid":false,"given":"Xiaobing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119359_bib1","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41556-025-01742-6","article-title":"Metabolic regulation of RIPK1","volume":"27","author":"Wang","year":"2025","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119359_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41422-022-00673-3","article-title":"Nuclear RIPK1 promotes chromatin remodeling to mediate inflammatory response","volume":"32","author":"Li","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.119359_bib3","article-title":"RIPK1-Associated inborn errors of innate immunity","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119359_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41418-025-01550-3","article-title":"Ripk1 is critical for preserving effector regulatory T cells and the suppressive transcriptional program in regulatory T cells","volume":"33","author":"Plaza-Sirvent","year":"2026","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.119359_bib5","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1038\/s41467-020-19935-y","article-title":"Ubiquitination of RIPK1 regulates its activation mediated by TNFR1 and TLRs signaling in distinct manners","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119359_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/ncb3608","article-title":"MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death","volume":"19","author":"Dondelinger","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119359_bib7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tcb.2016.01.006","article-title":"Holding RIPK1 on the ubiquitin leash in TNFR1 signaling","volume":"26","author":"Peltzer","year":"2016","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119359_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.139238","article-title":"Synthesis and evaluation of hybrid molecules as RIPK1 and HDACs dual inhibitors","volume":"1318","author":"Tang","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2026.119359_bib9","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1038\/s41467-019-11839-w","article-title":"Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119359_bib10","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1038\/s41467-024-51303-y","article-title":"The structure of mouse RIPK1 RHIM-containing domain as a homo-amyloid and in RIPK1\/RIPK3 complex","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119359_bib11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1548-x","article-title":"Cleavage of RIPK1 by Caspase-8 is crucial for limiting apoptosis and necroptosis","volume":"574","author":"Newton","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119359_bib12","doi-asserted-by":"crossref","first-page":"21049","DOI":"10.1021\/acs.jmedchem.4c01731","article-title":"Polypharmacological drug design guided by integrating phenotypic and restricted fragment docking strategies","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119359_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41586-019-1828-5","article-title":"Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease","volume":"577","author":"Lalaoui","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119359_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.molcel.2014.11.001","article-title":"The two faces of receptor interacting protein Kinase-1","volume":"56","author":"Weinlich","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119359_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00281-022-00910-2","article-title":"TNF in the liver: targeting a central player in inflammation","volume":"44","author":"Tiegs","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.ejmech.2026.119359_bib16","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s12276-022-00847-4","article-title":"The resurrection of RIP kinase 1 as an early cell death checkpoint regulator\u2014A potential target for therapy in the necroptosis era","volume":"54","author":"Ju","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119359_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118925","article-title":"Design, synthesis and anti-necroptosis evaluation of RIPK1 inhibitors derived from sunitinib","volume":"315","author":"Jiang","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119359_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117530","article-title":"Discovery of phenylisoxazolidine analogs targeting receptor interacting protein kinase 1 with anti-inflammatory activity","volume":"290","author":"Ma","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119359_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.365","article-title":"Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers","volume":"5","author":"Weisel","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejmech.2026.119359_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nchembio711","article-title":"Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury","volume":"1","author":"Degterev","year":"2005","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119359_bib21","doi-asserted-by":"crossref","first-page":"21766","DOI":"10.1021\/acs.jmedchem.5c02124","article-title":"Discovery of a 1H-Pyrazol-3-Amine derivative as a novel, selective, and orally available RIPK1 inhibitor for the treatment of inflammatory disease","volume":"68","author":"Tao","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119359_bib22","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1038\/s41467-022-34692-w","article-title":"Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119359_bib23","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1021\/acs.jmedchem.6c00339","article-title":"Potent Benzothiazole-Triazole RIPK1\/RIPK3 dual-targeting inhibitors for the treatment of systemic inflammatory response syndrome","volume":"69","author":"Hu","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119359_bib24","doi-asserted-by":"crossref","first-page":"14971","DOI":"10.1021\/acs.jmedchem.2c01518","article-title":"Small-molecule receptor-interacting protein 1 (RIP1) inhibitors as therapeutic agents for multifaceted diseases: current medicinal chemistry insights and emerging opportunities","volume":"65","author":"Shi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119359_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101748","article-title":"Receptor-interacting protein kinase 1 (RIPK1) regulates cervical cancer cells via NF-\u03baB\u2013TNF-\u03b1 pathway: an in vitro study","volume":"36","author":"Bai","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejmech.2026.119359_bib26","doi-asserted-by":"crossref","first-page":"15120","DOI":"10.1021\/acs.jmedchem.5c01340","article-title":"Development of potent and selective RIPK1 degraders targeting its nonenzymatic function for cancer treatment","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119359_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119359_bib28","doi-asserted-by":"crossref","first-page":"17595","DOI":"10.1039\/D5SC04859A","article-title":"Rational design of the linkers in targeting chimeras","volume":"16","author":"Duan","year":"2025","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119359_bib29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1021\/acs.biochem.2c00366","article-title":"Targeting scaffolding functions of enzymes using PROTAC approaches","volume":"62","author":"Kim","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119359_bib30","doi-asserted-by":"crossref","first-page":"16135","DOI":"10.1021\/acs.jmedchem.6c02076","article-title":"FDA approval of the first-ever PROTAC: vepdegestrant (ARV-471) marks a new era in targeted protein degradation","volume":"69","author":"Kumar","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119359_bib32","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1200\/JCO.2024.42.16_suppl.5011","article-title":"ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): initial results of a phase 1\/2 study","volume":"42","author":"Petrylak","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119359_bib33","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2021-151125","article-title":"A first-in-class STAT3 degrader KT-333 in development for treatment of hematologic cancers","volume":"138","author":"Liu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119359_bib34","doi-asserted-by":"crossref","first-page":"24848","DOI":"10.1021\/acs.jmedchem.5c01317","article-title":"Discovery of CFT8634, a potent, selective, and orally bioavailable heterobifunctional degrader of BRD9","volume":"68","author":"Jackson","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119359_bib35","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1021\/acs.jmedchem.6c00897","article-title":"RIMTAC: a novel degrader design platform by indirect VHL-recruitment via RIPK1","volume":"69","author":"Shen","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119359_bib36","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.immuni.2024.04.025","article-title":"A RIPK1-Specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death","volume":"57","author":"Mannion","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2026.119359_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55006-2","article-title":"Development of a RIPK1 degrader to enhance antitumor immunity","volume":"15","author":"Yu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119359_bib38","doi-asserted-by":"crossref","first-page":"19822","DOI":"10.1021\/acs.jmedchem.6c01156","article-title":"Discovery and development of first-in-class cereblon-recruiting RIPK1 degraders","volume":"69","author":"Lu","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119359_bib39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41568-025-00894-9","article-title":"Opportunities and challenges of targeting cGAS\u2013STING in cancer","volume":"26","author":"Lu","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119359_bib40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.apsb.2023.10.021","article-title":"Structure-based development of potent and selective Type-II kinase inhibitors of RIPK1","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119359_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41570-025-00784-6","article-title":"Lessons learned in linking PROTACs from discovery to the clinic","volume":"10","author":"Pike","year":"2026","journal-title":"Nat. Rev. Chem"},{"key":"10.1016\/j.ejmech.2026.119359_bib42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.ejmech.2026.119359_bib43","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/md17060362","article-title":"C-Phycocyanin suppresses the in vitro proliferation and migration of non-small-cell lung cancer cells through reduction of RIPK1\/NF-\u03baB activity","volume":"17","author":"Hao","year":"2019","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2026.119359_bib44","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232654","article-title":"Intratumoral injection of immunotherapeutics: state of the art and future directions","volume":"312","author":"Sheth","year":"2024","journal-title":"Radiology"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:27:58Z","timestamp":1791498478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":43,"alternative-id":["S0223523426008044"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119359","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the nonenzymatic scaffold function of RIPK1 via a VHL-recruiting PROTAC synergizes with immunotherapy in melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119359"}}